Antibodies Inc. today announced that it has completed the acquisition of the remaining outstanding shares of Biosensis Pty Ltd, which wholly owns and operates GroPep Bioreagents Pty Ltd and Biosensis LLC.
Antibodies Inc. initially acquired a controlling interest in Biosensis Pty Ltd in June 2025. The completion of this final transaction marks the full integration of Biosensis Pty Ltd into Antibodies Inc. and reinforces the commitment to the Life Science reagent market.
“This is an important milestone for Antibodies Inc” said Will Fry, President of Antibodies Inc. “Since acquiring a controlling stake last year, we have worked closely with the Biosensis team to align our operations and unlock new growth opportunities. We are pleased to now fully welcome Biosensis into Antibodies Inc.”
The acquisition is expected to enhance operational efficiencies, expand service capabilities, and create additional value. Biosensis and Gropep will continue to operate under their existing brands, ensuring continuity for customers and partners.
“The Biosensis Founders and I are incredibly proud of what our team has built,” said Patrick Schneider, CEO of Biosensis and GroPep Bioreagents. “Joining forces with Antibodies Inc. marks an exciting next chapter in our journey. We are already seeing the benefits of combining Biosensis and Antibodies Inc. products and technologies. This acquisition strengthens our ability to innovate quickly, scales our manufacturing capabilities, and delivers even greater value to the customers we serve.”
Financial terms of the acquisition were not disclosed.
About Biosensis Pty Ltd.
Biosensis and GroPep® Bioreagents Pty Ltd (a wholly owned Subsidiary of Biosensis Pty Ltd acquired in 2020) specialize in high-quality research and diagnostic reagents. Biosensis focuses on antibodies for research and proteomics platforms, ELISA kits, and tools for neuroscience and neurodegenerative disease research. GroPep® Bioreagents provides specialized growth factors and bioreagents for cell biology, biopharmaceutical production, and regenerative medicine.